Jubilant Pharmova Limited (NSE: JUBLPHARMA) reported a Revenue from Operations of ₹1,533.22 Crores, a boost of 18% growth from the previous year. The Net Loss for the business is ₹16.04 Crore from the profit of ₹50.80 Crore year on year. Earnings per Share is -₹0.98 for this quarter.
Jubilant Pharmova Limited Q3 FY23; Revenue Increased By 18%
Tags: pharmaceuticals
Related Post
- Natco Pharma Ltd Q2FY25; 83% rise in Profits
NATCO Pharma Limited (NATCO) is a vertically integrated, research and development focused pharmaceutical company engaged…
-
Muthoot Finance Ltd Q2FY25; 26% rise in Profits
Muthoot Finance is NBFC engaged in the business of providing gold loans. The company predominately…
-
Multi Commodity Exchange of India Ltd Q2FY25; 73% rise in Revenue
The MCX commenced operation in Nov,03 is India’s first listed, national-level, electronic exchange, and India’s…